ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025)

ARS Pharmaceuticals (SPRY) reported Operating Leases of $949000.0 for Q3 2025, down 11.47% sequentially from $1.1 million in Q2 2025.

ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 5 years of Operating Leases data on file, last reported at $949000.0 in Q3 2025.

For the quarter ending Q3 2025, Operating Leases changed N/A year-over-year to $949000.0; the trailing twelve-month figure through Sep 2025 stood at $949000.0 (changed N/A YoY), and the FY2023 full-year result was $37000.0, down 85.26% from the prior year.
Operating Leases eased to $949000.0 in Q3 2025, from $1.1 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $5.1 million in Q3 2021 to a low of $37000.0 in Q4 2023.
A 4-year average of $1.7 million and a median of $949000.0 in 2025 frame the typical range for Operating Leases.
Across the five-year window, Operating Leases soared 128.63% in 2022 and tumbled 96.41% in 2023, its largest moves.
Tracing SPRY's Operating Leases over 4 years: stood at $480000.0 in 2021, then slumped by 47.71% to $251000.0 in 2022, then slumped by 85.26% to $37000.0 in 2023, then soared by 2464.86% to $949000.0 in 2025.
Business Quant data shows SPRY's Operating Leases at $949000.0 in Q3 2025, $1.1 million in Q2 2025, and $37000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-

Download Data